

WEST[Help](#) [Logout](#) [Interrupt](#)[Main Menu](#) [Search Form](#) [Posting Counts](#) [Show S Numbers](#) [Edit S Numbers](#) [Preferences](#) [Cases](#)**Search Results -**

Term	Documents
CD40L.USPT,PGPB.	664
CD40LS.USPT,PGPB.	2
CD40.USPT,PGPB.	1799
CD40S	0
LIGAND.USPT,PGPB.	52101
LIGANDS.USPT,PGPB.	42671
FUSION.USPT,PGPB.	84832
FUSIONS.USPT,PGPB.	10679
PROTEIN.USPT,PGPB.	138960
PROTEINS.USPT,PGPB.	115218
IG.USPT,PGPB.	14726
((CD40L OR CD40 ADJ LIGAND) SAME (FUSION ADJ PROTEIN) SAME (IG OR IMMUNOGLOBULIN)).USPT,PGPB.	57

[There are more results than shown above. Click here to view the entire set.](#)**Database:**

US Patents Full-Text Database
US Pre-Grant Publication Full-Text Database
JPO Abstracts Database
EPO Abstracts Database
Derwent World Patents Index
IBM Technical Disclosure Bulletins

Search:

L3

Search History**DATE: Thursday, March 27, 2003** [Printable Copy](#) [Create Case](#)

Set Name Query

side by side

DB=USPT,PGPB; PLUR=YES; OP=ADJ

		<u>Hit Count</u>	<u>Set Name</u>
<u>L3</u>	(cd40L or cd40 adj ligand) same (fusion adj protein) same (ig or immunoglobulin)	57	<u>L3</u>
<u>L2</u>	L1.clm.	15	<u>L2</u>
<u>L1</u>	(cd40L or cd40 adj ligand) same (fusion adj protein)	137	<u>L1</u>

END OF SEARCH HISTORY

Set Name Query
side by side*DB=USPT,PGPB; PLUR=YES; OP=ADJ*

		<u>Hit Count</u>	<u>Set Name</u>
		result set	
<u>L3</u>	(cd40L or cd40 adj ligand) same (fusion adj protein) same (ig or immunoglobulin)	57	<u>L3</u>
<u>L2</u>	L1.clm.	15	<u>L2</u>
<u>L1</u>	(cd40L or cd40 adj ligand) same (fusion adj protein)	137	<u>L1</u>

END OF SEARCH HISTORY

Generate Collection

L3: Entry 42 of 57

File: USPT

Aug 22, 2000

DOCUMENT-IDENTIFIER: US 6106832 A

TITLE: Treatment of individuals exhibiting defective CD40L

Brief Summary Text (12):

The present invention further provides a method of treating an individual that has a syndrome in which the interaction of T cells and B cells is affected (such as X-linked hyper-IgM syndrome), comprising administering an effective amount of a soluble CD40L. Soluble forms of CD40L comprise the extracellular region of CD40L, and include, for example, fusion proteins comprising the extracellular region of CD40L and an Fc region of a human immunoglobulin, and CD40L multimers formed by adding a multimer-forming peptide to the extracellular region of CD40L.

CLAIMS:

2. The method of claim 1, wherein the soluble, oligomeric CD40 ligand comprises a fusion protein selected from the group consisting of the extracellular region of CD40 ligand and an Fc region of a human immunoglobulin, and a fusion protein formed by adding a multimer-forming peptide to the extracellular region of CD40L.

8. The method of claim 7 wherein the soluble, oligomeric CD40L comprises a fusion protein selected from the group consisting of the extracellular region of CD40 ligand and an Fc region of a human immunoglobulin, and a fusion protein formed by adding a multimer-forming peptide to the extracellular region of CD40L.

L3: Entry 41 of 57

File: USPT

Jul 24, 2001

DOCUMENT-IDENTIFIER: US 6264951 B1

TITLE: Methods of inhibiting CD40L binding to CD40 with soluble monomeric CD40L

Detailed Description Text (132):

These data indicate that the interaction of CD40 with its ligand is the principal molecular interaction responsible for T cell contact dependent induction of B cell growth and differentiation to both antigen-specific antibody production and polyclonal Ig secretion. As such, these data suggest that antagonists of this interaction, by soluble CD40, CD40/Fc fusion protein and possibly soluble CD40-L (monomeric), will significantly interfere with development of antibody responses. Therefore clinical situations where CD40, CD40/Fc fusion proteins and soluble CD40-L are suitable include allergy, lupus, rheumatoid arthritis, insulin dependent diabetes mellitus, and any other diseases where autoimmune antibody or antigen/antibody complexes are responsible for clinical pathology of the disease. Moreover, membrane-bound CD40-L or oligomeric soluble CD40-L will be useful to stimulate B cell proliferation and antibody production. As such, these forms of CD40-L are most useful for vaccine adjuvants and as a stimulating agent for mAb secretion from hybridoma cells.

WEST[Help](#)[Logout](#)[Interrupt](#)[Main Menu](#) [Search Form](#) [Posting Counts](#) [Show S Numbers](#) [Edit S Numbers](#) [Preferences](#) [Cases](#)**Search Results -**

Term	Documents
CD40L.USPT,PGPB.	664
CD40LS.USPT,PGPB.	2
CD40.USPT,PGPB.	1799
CD40S	0
LIGAND.USPT,PGPB.	52101
LIGANDS.USPT,PGPB.	42671
FUSION.USPT,PGPB.	84832
FUSIONS.USPT,PGPB.	10679
PROTEIN.USPT,PGPB.	138960
PROTEINS.USPT,PGPB.	115218
IG.USPT,PGPB.	14726
((CD40L OR CD40 ADJ LIGAND) SAME (FUSION ADJ PROTEIN) SAME (IG OR IMMUNOGLOBULIN)).USPT,PGPB.	57

[There are more results than shown above. Click here to view the entire set.](#)**Database:**

US Patents Full-Text Database
 US Pre-Grant Publication Full-Text Database
 JPO Abstracts Database
 EPO Abstracts Database
 Derwent World Patents Index
 IBM Technical Disclosure Bulletins

Search:

L3

Search History**DATE: Thursday, March 27, 2003** [Printable Copy](#) [Create Case](#)